Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Ltd Partners with Tabuk Pharmaceuticals to Commercialise Its Speciality Generic Medicines in the Middle East","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SAUDI ARABIA","productType":"Peptide","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"$3,335.0 million","upfrontCash":"$2,335.0 million","newsHeadline":"Biocon Biologics to Acquire Viatris\u2019 Biosimilars Assets for up to USD 3.335 billion in Stock and Cash","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"February 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Civica Rx","sponsor":"GeneSys Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"March 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Soliqua\u00ae Data Shows Improved Blood Sugar Control Without Weight Gain Versus Premixed Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris and Biocon Biologic Announce Approval for First Interchangeable Biosimilar Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"July 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Civica Rx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Peptide","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris Wins Court Decisions on Sanofi Appeals of Lantus\u00ae Patent Invalidations","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee\u00ae (Insulin Glargine Injection), 100 units\/mL (U-100), 3 mL Prefilled Pens, Due to the Potential for a Missing Label in the Batch","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"January 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Initiates Pivotal Clinical Trial for Biosimilar Insulin Glargine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"March 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"HEC Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Announces Subject Dosing Complete For Pivotal Clinical Trial Of Biosimilar Insulin Glargine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"August 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Launches New Long-Acting Insulin Drug in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Insulin Glargine

    Menu

    Insulin Glargine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sanofi

              Contact Supplier
              • Development Update
              Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
              Contact Supplier Contact Supplier
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sanofi Launches New Long-Acting Insulin Drug in India

              Details:

              Soliqua is a combination of insulin glargine, a basal insulin analog, and lixisenatide, a GLP-1 receptor agonist. It is indicated as treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabetes.

              Lead Product(s): Insulin Glargine,Lixisenatide

              Therapeutic Area: Endocrinology Product Name: Soliqua

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 27, 2023

              Sanofi Company Banner

              Iran Expo

              Not Confirmed

              envelop Contact Supplier

              Sanofi

              Contact Supplier
              • Development Update
              Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
              Contact Supplier Contact Supplier
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Soliqua® Data Shows Improved Blood Sugar Control Without Weight Gain Versus Premixed Insulin

              Details:

              Participants were randomized to switch from their prior insulin to either Soliqua once daily or premixed insulin twice daily, with starting doses determined and adjusted weekly. Any metformin or SGLT-2i treatment was maintained through the study period.

              Lead Product(s): Insulin Glargine,Lixisenatide

              Therapeutic Area: Endocrinology Product Name: Soliqua

              Highest Development Status: Undisclosed Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 28, 2021

              Sanofi Company Banner

              Iran Expo

              Not Confirmed

              envelop Contact Supplier

              Ypsomed

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative

              Details:

              Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and to ensure redundancy of supply, Ypsomed will provide injector dosing pens from their manufacturing facilities.

              Lead Product(s): Insulin Glargine

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Peptide

              Partner/Sponsor/Collaborator: Civica Rx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership January 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lannett Company, Inc.

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lannett Announces Subject Dosing Complete For Pivotal Clinical Trial Of Biosimilar Insulin Glargine

              Details:

              Biosimilar insulin glargine is the most significant opportunity in the company's current pipeline. Recent estimated U.S. sales of long acting insulin glargine (Glaricon) are approximately $10 billion annually, according to IQVIA, although manufacturer reported sales are less.

              Lead Product(s): Insulin Glargine

              Therapeutic Area: Endocrinology Product Name: Glaricon

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: HEC Group

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lannett Company, Inc.

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lannett Initiates Pivotal Clinical Trial for Biosimilar Insulin Glargine

              Details:

              The first study, which the FDA reviewed, suggested that the HEC insulin glargine product would be biosimilar to US-approved Lantus® (the reference biologic) in terms of meeting the study's pharmacokinetics (PK) and pharmacodynamics (PD) endpoints.

              Lead Product(s): Insulin Glargine

              Therapeutic Area: Endocrinology Product Name: HEC-Glargine

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Civica Rx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership

              Details:

              Civica will produce three insulins – glargine, lispro and aspart (biologics corresponding to, and interchangeable with, Lantus, Humalog and Novolog respectively) – each of which will be available both in vials and prefilled pens.

              Lead Product(s): Insulin Glargine

              Therapeutic Area: Endocrinology Product Name: Insulin Glargine-Generic

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: GeneSys Biologics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing March 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viatris

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

              Details:

              The acquisition of biosimilars assets of Viatris significantly strengthens BBL’s position in providing affordable access to patients through its portfolio in diabetes, oncology, immunology and other non-communicable diseases including Semglee (Insulin Glargine-yfgn).

              Lead Product(s): Insulin Glargine

              Therapeutic Area: Endocrinology Product Name: Semglee

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Biocon

              Deal Size: $3,335.0 million Upfront Cash: $2,335.0 million

              Deal Type: Acquisition February 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viatris

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee® (Insulin Glargine Injection), 100 units/mL (U-100), 3 mL Prefilled Pens...

              Details:

              The Semglee® (insulin glargine injection), is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus and is packaged in prefilled pens.

              Lead Product(s): Insulin Glargine

              Therapeutic Area: Endocrinology Product Name: Semglee

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Biocon

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viatris

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations

              Details:

              Decisions reaffirm Viatris' ability to provide patient access to interchangeable for the reference brand, Lantus®, allowing for substitution at the pharmacy counter. Semglee® is indicated to help control high blood sugar with type 1 diabetes and type 2 diabetes.

              Lead Product(s): Insulin Glargine

              Therapeutic Area: Endocrinology Product Name: Semglee

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tabuk Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Saudi Arabia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biocon Ltd Partners with Tabuk Pharmaceuticals to Commercialise Its Speciality Generic Medicines in the Middle East

              Details:

              Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products including Glaricon and be responsible to register, importing, and promoting them in Saudi Arabia and other Middle East countries.

              Lead Product(s): Insulin Glargine

              Therapeutic Area: Endocrinology Product Name: Glaricon

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Biocon

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement December 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY